Acute Lymphoblastic Leukemia Discussion on the Use of Asparaginase Therapy in Young and Older Adults

Acute Lymphoblastic Leukemia Discussion on the Use of Asparaginase Therapy in Young and Older Adults

Friday, December 9, 2022
Webinar -- 11:30 AM CT


  • Welcome and Introduction
  • Applying Lessons and Experience in Pediatric Patients to the Treatment of AYA and Adult Patients With ALL Daniel J. DeAngelo, MD, PhD
  • Practical Considerations for Administration of Asparaginase-Based Therapy to Patients with ALL: Hypersensitivity or Intolerance or Inactivation? Kjeld Schmiegelow, MD
  • Strategies to Mitigate Adverse Events with Asparaginase Treatment in Patients With ALL Emily Curran, MD
  • Final Panel Discussion and Audience Question and Answer Session


Program Director
Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‚ÄźFarber Cancer Institute
Boston, Massachusetts

Emily Curran, MD

Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Kjeld Schmiegelow, MD, DMSci

Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with ALL.

Target Audience
This program is intended for physicians and other healthcare professionals who care for adolescent/young adult and adult patients with acute lymphoblastic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select, optimize, and apply asparaginase-containing regimens for adolescent/young adult and adult patients
  • Identify optimal methods of measuring and monitoring subclinical hypersensitivity or silent inactivation
  • Plan optimal approaches to achieve continued and active asparaginase treatment, including activity level testing and premedication
  • Integrate into practice expert recommendations and insights from available data on reexposure of asparaginase treatments or use of recombinant asparaginase formulations
  • Discuss recent clinical evidence and current recommendations for optimizing the therapeutic regimens for adolescent/young adult patients with ALL with pediatric-inspired protocols


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.